Skip to main content

Table 4 Summary of studies to assess causal prophylactic efficacy of ELQ-331 and other prodrugs

From: ELQ-331 as a prototype for extremely durable chemoprotection against malaria

  1. The first sporozoite challenge experiment (upper table segment) assessed the efficacy of 30 mg/kg of ELQ-331 and two other prodrugs on day 137 (dosing Trial 1) and of ELQ-331 on Day 48 (dosing trial 2). The second experiment (middle table segment), assessed 10 mg/kg ELQ-331 (dosing Trial 3); and the third experiment (lower table segment) compared 2.5, 5, and 10 mg/kg ELQ-331 doses (dosing Trial 4). Results show more durable protection with ELQ-331 (30 mg/kg, > 4 months; 10 mg/kg, > 3 months) than other tested prodrugs, and MECLAI-C between 60 and 80 nM (see text). The total flux values (photons/s) for each displayed image are presented in Additional file 2
  2. aWhole animal imaging was the a priori measure of efficacy, however, blood smear revealed occult infection—see text
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us